Drug Trial Radar · NCT04159519
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Last checked: Nov 20, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
170
Actual
Start
Jul 27, 2020
Primary completion
Jan 31, 2023
Study completion Jan 31, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe eosinophilic asthma on Fasenra® treatment, while maintaining asthma control.
Conditions
- Asthma
- Severe Eosinophilic Asthma
Interventions
Symbicort®Drug
Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
Fasenra®Drug
Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.
Ventolin®Drug
Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction PeriodTime frame: At Week 32
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Brest, France
Research Site
Dijon, France
Research Site
Le Kremlin-Bicêtre, France
Research Site
Lille, France
Research Site
Lyon, France
Research Site
Pessac, France
Research Site
Berlin, Germany
Research Site
Bonn, Germany
Research Site
Cottbus, Germany
Research Site
Hamburg, Germany
Research Site
Hamburg, Germany
Research Site
Hanover, Germany
Research Site
Jena, Germany
Research Site
Mainz, Germany
Research Site
Marburg, Germany
Research Site
München, Germany
Research Site
Bergamo, Italy
Research Site
Naples, Italy
Research Site
Roma, Italy
Research Site
Belfast, United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
London, United Kingdom
Research Site
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.